Trials / Completed
CompletedNCT02221271
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Nihon Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluate the Functional Grade（FG） and Arm Grade（AG） et al. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NPB-01 |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-08-20
- Last updated
- 2017-04-12
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02221271. Inclusion in this directory is not an endorsement.